Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
0 competitors in Chronic Graft-Versus-Host Disease (cGVHD)
View Full LandscapeTarget Indication
Chronic Graft-Versus-Host Disease (cGVHD)
Clinical Trial
NCT06619561Last updated: 1/2/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Romvimza
Romvimza is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability.